Supernus Pharmaceuticals (SUPN) Lifted to “Buy” at Janney Montgomery Scott

Janney Montgomery Scott upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a neutral rating to a buy rating in a research note issued to investors on Monday, Marketbeat Ratings reports. Janney Montgomery Scott currently has $47.00 price target on the specialty pharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the company. ValuEngine cut Supernus Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, December 1st. B. Riley restated a buy rating and issued a $50.00 price target on shares of Supernus Pharmaceuticals in a research note on Monday, November 20th. Zacks Investment Research cut Supernus Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Friday, November 10th. Stifel Nicolaus upgraded Supernus Pharmaceuticals from a hold rating to a buy rating and set a $47.00 price target for the company in a research note on Tuesday, November 7th. Finally, SunTrust Banks restated a buy rating and issued a $61.00 price target on shares of Supernus Pharmaceuticals in a research note on Friday, November 3rd. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $49.60.

Shares of Supernus Pharmaceuticals (NASDAQ SUPN) traded down $0.65 during trading hours on Monday, reaching $36.45. The company’s stock had a trading volume of 277,400 shares, compared to its average volume of 606,624. The stock has a market capitalization of $1,901.82, a PE ratio of 35.00, a price-to-earnings-growth ratio of 1.57 and a beta of 1.19. Supernus Pharmaceuticals has a 1-year low of $21.60 and a 1-year high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. The business had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The business’s revenue was up 41.5% compared to the same quarter last year. equities analysts predict that Supernus Pharmaceuticals will post 1.07 EPS for the current fiscal year.

In other Supernus Pharmaceuticals news, SVP Padmanabh P. Bhatt sold 5,000 shares of the business’s stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $49.86, for a total transaction of $249,300.00. Following the completion of the sale, the senior vice president now owns 12,500 shares of the company’s stock, valued at $623,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Gregory S. Patrick sold 50,000 shares of the business’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $47.60, for a total value of $2,380,000.00. The disclosure for this sale can be found here. Insiders own 6.70% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. lifted its position in shares of Supernus Pharmaceuticals by 0.5% in the second quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock worth $289,962,000 after buying an additional 31,331 shares in the last quarter. Vanguard Group Inc. raised its position in Supernus Pharmaceuticals by 39.1% during the second quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock valued at $150,873,000 after purchasing an additional 984,200 shares during the period. State Street Corp raised its position in Supernus Pharmaceuticals by 3.1% during the second quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock valued at $60,230,000 after purchasing an additional 42,165 shares during the period. Rice Hall James & Associates LLC raised its position in Supernus Pharmaceuticals by 24.5% during the second quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock valued at $58,675,000 after purchasing an additional 267,971 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Supernus Pharmaceuticals by 10.6% during the second quarter. Dimensional Fund Advisors LP now owns 1,268,082 shares of the specialty pharmaceutical company’s stock valued at $54,654,000 after purchasing an additional 122,042 shares during the period. Institutional investors and hedge funds own 98.34% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Supernus Pharmaceuticals (SUPN) Lifted to “Buy” at Janney Montgomery Scott” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3079702/supernus-pharmaceuticals-supn-lifted-to-buy-at-janney-montgomery-scott.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.